Abstract 917P
Background
Patients with oral cavity squamous cell carcinoma (OCSCC) are at high risk of death within 5 years of treatment. Previous works have demonstrated that spatial arrangement of tumor-infiltrating lymphocytes (TILs) and surrounding nuclei (e.g, cancer nuclei, macrophages, fibroblasts) is prognostic of overall survival (OS) in different types of cancer, including oropharyngeal and laryngeal. In this work, we evaluated the prognostic ability of a computerized strategy that characterizes the spatial arrangement of TILs & non-TILs on digitized H&E-stained slides of patients with OCSCC.
Methods
Whole slide images (WSIs) from a cohort of 283 patients with OCSCC were retrospectively collected from the Cancer Genome Atlas (TCGA, D1). Additionally, WSIs from 136 patients with OCSCC were obtained from Vanderbilt University Medical Center (VUMC, D2). D1 was used to train a prognostic model while D2 was used for independent validation. Computer algorithms automatically identified 2 types of nuclei (TILs & non-TILs) and built clusters for each nucleus type based on proximity. Metrics related to density, intersection, and neighborhood were computed from these clusters. A proportional hazard Cox regression model, regularized via the least absolute shrinkage and selection operator, was trained to predict risk of death. The percentile 66 risk score on D1 was used as a threshold for stratifying patients on D2 as either low or high risk. Survival analysis was then used to evaluate the association with OS.
Results
Patients in D2 defined as “low risk” (57%) based on spatial arrangement of TILs has significantly better OS than those identified as “high risk” (43%) with hazard ratio=3.84 (95% confidence interval: 1.39-10.6, p<0.01). Multivariable survival analysis showed that this model was prognostic independent of age and overall, T, and N stages with HR=2.88 (95% CI: 1.10-7.56, p=0.03).
Conclusions
A computerized image analysis model based on measurements of spatial arrangement of TILs & non-TILs was found to be prognostic in patients with OCSCC. With more modeling and development, this model may provide a risk classifier for use in routine clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Madabhushi.
Funding
US National Institutes of Health, US Department of Defense.
Disclosure
A. Madabhushi: Financial Interests, Personal, Advisory Board, Serve on SAB and consult: SimbioSys; Financial Interests, Personal, Advisory Board: Aiforia, Picture Health; Financial Interests, Personal, Full or part-time Employment: Picture Health; Financial Interests, Personal, Ownership Interest: Picture Health, Elucid Bioimaging, Inspirata Inc; Financial Interests, Personal, Royalties: Picture Health, Elucid Bioimaging; Financial Interests, Institutional, Funding: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Presenter: Gema Bruixola
Session: Poster session 03
919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Presenter: Paolo Bossi
Session: Poster session 03
920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samples
Presenter: Sewanti Limaye
Session: Poster session 03
Resources:
Abstract
921P - Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Presenter: Michael Saerens
Session: Poster session 03
922P - Genomic instability as a biomarker for advanced cancer of the head and neck
Presenter: Filippo Dall'Olio
Session: Poster session 03
923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN
Presenter: Natasha Honoré
Session: Poster session 03
924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Presenter: Darren Wan-Teck Lim
Session: Poster session 03
925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Presenter: Laville Adrien
Session: Poster session 03
926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Presenter: Haruhi Furukawa
Session: Poster session 03
927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Presenter: Laia Alemany
Session: Poster session 03